- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02153866
The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine
Nowadays these are some vaccines being vaccinated simultaneously, and a doubt is aroused if the safety and immunogenicity are same between inoculating several vaccines simultaneously and inoculating individually. So we carry out this study.
The purpose of this study is to evaluate the difference of safety and immunogenicity on vaccinating rotavirus vaccine simultaneously with measles-rubella vaccine(MR) or measles-mumps-rubella vaccine(MMR) compared to vaccinating rotavirus vaccine, MR or MMR individually.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Quality control plan:
- All vaccinators should get professional training held by local Health Bureau, and be qualified by local Health Bureau.
- All the clinical trial related staffs are trained by provincial or prefectural Center for Disease Control and prevention (CDC) at the beginning.
- Provincial and prefectural CDCs conduct supervision at each step, especially during field vaccination and Adverse Events Following Immunization (AEFI) investigation.
- Data valid check is designed to work in the database inputting, double entry and validation is also required.
- The field works are conduct under SOP (Standard Operating Procedures), The SOP for vaccination procedures which include vaccinee recruitment and vaccination practice etc. is 'Immunization Work Specification' issued by China Ministry of Health in 2005. The SOP for AEFI surveillance is 'AEFI surveillance guideline' issued by China Ministry of Health in 2010.
Statistical plan
- Safety evaluation The analytic data include all reactions or events within 30 days after vaccination, compare the incidence of reactions among different vaccines, the statistical method is chi-square.
- Immunogenicity evaluation Compare the antibody positive rate and Geometric Mean Concentration between pre-vaccination and post-vaccination, and among different vaccine combinations.
safety evaluation method
At the time of vaccination, vaccinees were instructed to report any adverse event to physicians or vaccination providers. Adverse events that were fatal or that resulted in disability and clusters of events (i.e., notably high numbers of similar adverse events related to a certain vaccine) were required to be reported within 2 hours after their occurrence. The following adverse events were required to be reported within 2 days after their occurrence: anaphylaxis or other allergic reactions occurring within 24 hours after vaccination; fever (axillary temperature, >38.5°C), angioedema, or a local injection-site reaction (diameter, >2.5 cm) occurring within 5 days after vaccination; purpura, an Arthus reaction, febrile convulsion, seizure, or polyneuritis occurring within 15 days after vaccination. Other reactions that were common and minor (e.g., mild pain and fatigue) were not required to be reported.
- Immunogenicity evaluation
Enzyme-linked immunosorbent assay (abbreviated as ELSIA) is used to quantitatively test immunoglobulin G (IgG) of measles, rubella, mumps, test kit is provided by Virion\Serion company. Rotavirus Immunoglobulin A (RV-IgA) is used to test the antibody of rotavirus.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 8~9 months healthy child
- Subjects or guardians who can and will comply with the requirements of the protocol
- Without vaccination history of rotavirus vaccine, measles-rubella vaccine and measles-mumps-rubella vaccine.
- Axillary temperature is under 37.0℃.
- Accord with the requirement of drug manual of rotavirus vaccine,measles-rubella vaccine and measles-mumps-rubella vaccine.
Exclusion Criteria:
- Allergic to any component of the vaccines.
- Women of pregnancy, lactation or about to be pregnant in 60 days.
- Infected by some rash disease within one month.
- Known severe immunodeficiency (e.g., from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, or long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised).
- Any prior administration of immunoglobulins, any other vaccines or experimental drugs in the last 4 weeks.
- Family history of seizures or progressive neurological disease.
- Diarrheal caused by rotavirus or lasting for 3 or more days.
- Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: rotavirus
vaccinate one dose rotavirus vaccine for each of 700 participants aged 8~9months
|
3ml/dose, oral
|
Placebo Comparator: measles-rubella
vaccinate one dose measles-rubella vaccine for each of 350 participants aged 8~9 months.
|
0.5ml per dose, subcutaneous injection
Other Names:
|
Placebo Comparator: measles-mumps-rubella
vaccinate one dose measles-mumps-rubella vaccine for each of 350 participants aged 8~9 months.
|
0.5ml per dose, subcutaneous injection
Other Names:
|
Experimental: rotavirus, measles-rubella
simultaneously vaccinate one dose rotavirus vaccine and one dose measles-rubella vaccine for each of 700 participants aged 8~9 months.
|
3ml/dose, oral
0.5ml per dose, subcutaneous injection
Other Names:
|
Experimental: rotavirus, measles-mumps-rubella
simultaneously vaccinate one dose rotavirus vaccine and one dose measles-mumps-rubella vaccine for each of 700 participants aged 8~9 months.
|
3ml/dose, oral
0.5ml per dose, subcutaneous injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the occurrence rate of general reaction of different vaccination groups
Time Frame: 1 months after vaccination
|
general reaction includes fever (axillary temperature> 3.85℃), local injection-site reaction (diameter> 2.5 cm) etc.
|
1 months after vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the occurrence rate of severe adverse event of different vaccination groups
Time Frame: 1 month after vaccination
|
severe reaction include: anaphylaxis, angioedema, purpura, an Arthus reaction, febrile convulsion, seizure, polyneuritis, other adverse events cause fatal, result in disability or clusters of events (i.e., notably high numbers of similar adverse events related to a certain vaccine)
|
1 month after vaccination
|
The variation of antibody Geometric Mean Titer compared between before and after vaccination
Time Frame: 1 month after vaccination
|
this measure is used to assess the immunogenicity of different groups
|
1 month after vaccination
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: rui ao, Master, Sichuan Provincial Center for Disease Control and Prevention
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- cnbg-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rotavirus
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesUnited States, Finland, Germany, Taiwan, Spain, Costa Rica, Korea, Republic of, Japan
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesJapan
-
GlaxoSmithKlineCompletedRotavirus Infection | Rotavirus VaccinesUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University of Padova; Centers for Disease Control and Prevention; Aga Khan University and other collaboratorsCompleted
-
Merck Sharp & Dohme LLCTerminated
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesPhilippines
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesPhilippines
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesKorea, Republic of
Clinical Trials on rotavirus vaccine
-
Federico II UniversityMerck Sharp & Dohme LLCNot yet recruitingMeningococcal Infections | Rotavirus Infections | Vaccination
-
Centre for Infectious Disease Research in ZambiaImperial College London; Christian Medical College, Vellore, IndiaCompletedDiarrhoeal DiseaseZambia
-
GlaxoSmithKlineCompletedInfections, RotavirusFinland, Germany, Spain, Italy, France, Czech Republic
-
GlaxoSmithKlineCompletedRotavirus InfectionsSouth Africa
-
Merck Sharp & Dohme LLCTerminated
-
Butantan InstituteCompleted
-
Serum Institute of India Pvt. Ltd.Completed
-
GlaxoSmithKlineCompletedInfections, RotavirusVietnam
-
GlaxoSmithKlineCompleted